Novo Nordisk to present new data from sickle cell disease and haemophilia trials at the 66th American Society of Hematology (ASH) annual meeting

HIBISCUS phase 2 data evaluating the safety profile and efficacy of etavopivat in adult and adolescent patients with sickle cell diseaseFRONTIER4 interim phase 3 results evaluating safety profile and efficacy of Mim8 prophylaxis administered once every two weeks for patients with haemophilia A with or without inhibitorsExplorer7 phase 3 study results evaluating the safety profile and efficacy of concizumab in patients with haemophilia A or B with inhibitors, with or without target joints at baseline Bagsvær ...